Call to Extraordinary General Meeting
OASMIA PHARMACEUTICAL AB (publ.) CALL TO EXTRAORDINARY GENERAL MEETING
The shareholders in Oasmia Pharmaceutical (publ) org no 556332-6676 are hereby called to an Extraordinary General Meeting at floor 7, Vallongatan 1, Uppsala, on Friday January 30, at 15.00 CET. Registration will commence at 14.30.
Registration
Shareholders who want to take part in the negotiations at the Meeting must:
- Be listed in the share register held by VPC by January 23 2009 at the latest.
- Register his or hers participation with the company on the address Vallongatan 1, 752 28 Uppsala, by fax no: +46 18 51 08 73, by telephone no: +46 18 50 54 40 or by e-mail: info@oasmia.com by January 28 2009, at 16.00 CET at the latest.
When registering should name, address, telephone number, personal or organization number and number of shares be given. Shareholders or their representatives have the right to bring at most two assistants. Assistants must be registered in the same way as shareholders.
Nominee shares
Nominee shareholders must register their shares in their own name temporarily to invoke voting rights at the Meeting. Such registration must be carried out by VPC AB by January 23 2009 at the latest.
Representatives
Shareholders who want to use their voting rights through representatives at the Meeting should write a signed and dated authorization. The authorization may be one year old at the most and should be brought to the Meeting in original. Authorization forms are available at Oasmia.
Number of shares
The company shares are only issued in series A. Every share in the company entitles one vote at the Meeting. There are in total 33 500 000 shares in the company.
Items
1. Opening of the meeting
2. Election of chairman for the Meeting
3. Establishment and approval of the number of votes
4. Approval of the agenda
5. Election of one or two persons to check the minutes
6. Test whether the Meeting has been orderly called or not
7. Decision about guidelines for remuneration of managers
8. Closing of the Meeting
The Board's proposal regarding item 7 in the agenda.
The Board of Directors proposes the following guidelines for determination of salary and other compensations for the Chief Executive Officer and other managers. The guidelines concerns the period from the Annual General Meeting 2008 to the Annual General Meeting 2009.
Salary and other benefits
Remuneration to the CEO and other managers shall be constituted by a fixed salary. In addition to fixed salary no other compensations or benefits shall be issued and no pension allocations shall be made.
Notice periods and severance pay
Upon notice from the company the notice period for the CEO shall be at the most 24 months. Upon notice from the CEO the notice period shall be at the most six months. For other managers the notice period shall be six months if the notice is made by the company and three months of the notice is made by the manager. No particular severance pay shall be issued.
Incentive programs
Decisions about possible share and share price related incentive programs aimed towards managers shall be made by the General Meeting.
Remuneration committee.
The Board of Directors does not have any remuneration committee. The Board of Directors deems that they can fill the function that otherwise would be filled by a remuneration committee. The principles for the setting of salaries concerning the CEO and other managers shall be found in a policy established by the Board of Directors.
Deviation in specific cases
The Board of Directors has the right to deviate from these guidelines if there are special circumstances. If such circumstances exist, information about it and the reason for the deviation shall be disclosed to the next Annual General Meeting.
Documents
The Board's proposal regarding item 7 is available at the company (address above) and the company website www.oasmia.com.
Uppsala, January 12, 2009
The Board of Directors Oasmia Pharmaceutical AB (publ.)
The call is available in PDF format here.
